Edwards Lifesciences Corporation v. Meril Life Sciences Pvt. Ltd.

Background

Edwards Lifesciences Corporation and Edwards Lifesciences LLC sued Meril Life Sciences Pvt. Ltd. and Meril, Inc. The opinion says Meril created a Myval-branded transcatheter heart valve, while Edwards supplies medical devices, including SAPIEN transcatheter prosthetic heart valves.

Edwards’s claims included trademark infringement under the federal trademark statute and common law, false advertising and unfair competition under the federal Lanham Act, and unfair competition and false advertising under California law. Edwards alleged that Meril used the phrase “Partner the Future” at two cardiovascular conferences and in related promotional materials. Edwards also alleged that Meril made false or misleading statements at cardiovascular conferences and online, including through websites, social-media accounts, and email messages.

Partial Summary Judgment

Edwards moved for partial summary judgment—a ruling that certain issues had no genuine dispute of material fact—as to two elements of its Lanham Act false-advertising and unfair-competition claims: whether Meril made false statements and whether those statements were used in interstate commerce.

The court denied the request concerning falsity. A Lanham Act false-advertising claim requires, among other things, a false statement of fact in a commercial advertisement. The court found that Edwards’s motion did not address whether the challenged statements qualified as commercial advertisements. Edwards argued that point for the first time in its reply brief, which the court would not consider for that purpose.

The court also denied the request concerning interstate commerce. It found that Edwards had not shown that statements made only at cardiovascular conferences were necessarily made in interstate commerce. The record did not clearly show how widely those statements were distributed, and Edwards did not explain whether or how the statements substantially affected interstate commerce. After denying both requests, the court declined to decide additional discrete issues through piecemeal summary judgment because factual disputes remained.

Motions to Seal

The court applied the “compelling reasons” standard because the documents were connected to a dispositive motion. That standard requires specific reasons for secrecy that outweigh the public’s strong interest in access to judicial records. The court said confidentiality designations alone were insufficient.

The court’s final dispositions were as follows:

- Docket No. 209: denied. - Docket No. 239: denied. - Docket No. 243: granted. - Docket Nos. 217 and 225: granted in part and denied in part.

The court found compelling reasons to seal specified information concerning Meril’s clinical-trial strategies, raw medical data, regulatory strategies, regulatory submissions, and related proprietary information. It rejected requests that relied only on confidentiality designations or that sought to seal nonconfidential material, including general references to admissions that data was inaccurate. The parties were ordered to file public versions of the identified documents within seven days after the order was filed.